EXEMESTANE - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for exemestane and what is the scope of freedom to operate?

Exemestane is the generic ingredient in two branded drugs marketed by Pfizer, Alvogen, Amneal Pharms, Breckenridge, Cipla, Dr Reddys Labs Sa, Eugia Pharma, Hikma, Qilu, Rising, Upsher Smith Labs, and Zydus Pharms, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are fifteen drug master file entries for exemestane. Thirteen suppliers are listed for this compound.

Sponsor	Phase
Breast Cancer Research Foundation	Phase 2
QuantumLeap Healthcare Collaborative	Phase 2
NRG Oncology	Phase 2

Sponsor

Phase

Breast Cancer Research Foundation

Phase 2

QuantumLeap Healthcare Collaborative

Phase 2

NRG Oncology

Phase 2

US Patents and Regulatory Information for EXEMESTANE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Qilu	EXEMESTANE	exemestane	TABLET;ORAL	213547-001	Apr 13, 2020	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Upsher Smith Labs	EXEMESTANE	exemestane	TABLET;ORAL	209208-001	Jul 26, 2017	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Hikma	EXEMESTANE	exemestane	TABLET;ORAL	077431-001	Apr 1, 2011	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Alvogen	EXEMESTANE	exemestane	TABLET;ORAL	200898-001	Jul 28, 2014		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Dr Reddys Labs Sa	EXEMESTANE	exemestane	TABLET;ORAL	208764-001	Aug 8, 2019		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	AROMASIN	exemestane	TABLET;ORAL	020753-001	Oct 21, 1999	⤷ Sign Up	⤷ Sign Up
Pfizer	AROMASIN	exemestane	TABLET;ORAL	020753-001	Oct 21, 1999	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Applicant

Tradename

Generic Name

Dosage

NDA

Approval Date

Patent No.

Patent Expiration

TABLET;ORAL

Oct 21, 1999

⤷ Sign Up

TABLET;ORAL

Oct 21, 1999

⤷ Sign Up

>Applicant

>Tradename

>Generic Name

>Dosage

>NDA

>Approval Date

>Patent No.

>Patent Expiration

Subscribe to access the full database, or Sign Up

US Patents:	0
Tradenames:	2
Applicants:	12
NDAs:	12
Drug Master File Entries:	15
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	100
Clinical Trials:	254
Patent Applications:	5,922
Drug Prices:	Drug price trends for EXEMESTANE
What excipients (inactive ingredients) are in EXEMESTANE?	EXEMESTANE excipients list
DailyMed Link:	EXEMESTANE at DailyMed

Drug Class	Aromatase Inhibitor
Mechanism of Action	Aromatase Inhibitors

EXEMESTANE - Generic Drug Details

What are the generic sources for exemestane and what is the scope of freedom to operate?

Summary for EXEMESTANE

Recent Clinical Trials for EXEMESTANE

Pharmacology for EXEMESTANE

Anatomical Therapeutic Chemical (ATC) Classes for EXEMESTANE

US Patents and Regulatory Information for EXEMESTANE

Expired US Patents for EXEMESTANE

Make Better Decisions: Try a trial or see plans & pricing